Nkarta Inc

73 articles about Nkarta Inc

• Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

  8/10/2023

  Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies, reported financial results for the second quarter ended June 30, 2023.

• Nkarta to Participate at Upcoming Investor Conference - August 3, 2023

  8/3/2023

  Nkarta, Inc.today announced its participation at an upcoming investor conference.

• Nkarta Appoints Alyssa Levin Chief Financial and Business Officer

  7/5/2023

  Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced the appointment of Alyssa Levin as Chief Financial and Business Officer.

• Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

  6/27/2023

  Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced positive updated data from its Phase 1 study of NKX101 to treat patients with relapsed or refractory (r/r) acute myeloid leukemia (AML).

• Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program

  6/26/2023

  Nkarta, Inc. (Nasdaq: NKTX) today announced that it will host a conference call on Tuesday, June 27, 2023 at 8:00 a.m. ET to review updated clinical data from the ongoing clinical trial of NKX101, its allogeneic, off-the-shelf CAR NK cell therapy candidate engineered to target NKG2D ligands on cancer cells.

• Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

  6/10/2023

  Nkarta, Inc. announced presentations highlighting preliminary data based on a November 2022 data cut-off from its Phase 1 dose escalation clinical trial of NKX019 at two scientific conferences: the European Hematology Association 2023 Hybrid Congress and the 17th International Conference on Malignant Lymphoma.

• Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

  5/11/2023

  Nkarta, Inc. announced that it will present preliminary data from its Phase 1 dose escalation clinical trial of NKX019 at two upcoming scientific conferences in June 2023: the European Hematology Association 2023 Hybrid Congress and the 17th International Conference on Malignant Lymphoma.

• Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights

  5/11/2023

  Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies, reported financial results for the first quarter ended March 31, 2023.

• Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting

  4/17/2023

  Nkarta, Inc. (Nasdaq: NKTX) today announced the presentation of two preclinical data abstracts focused on its natural killer cell pipeline and proprietary manufacturing technology at the 2023 American Association of Cancer Research (AACR) Annual Meeting.

• Nkarta to Participate at Upcoming April 2023 Investor Conferences

  4/13/2023

  Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced its participation at two upcoming investor conferences:

• Nkarta Announces Departure of Chief Financial & Business Officer

  3/30/2023

  Nkarta, Inc. announced that Nadir Mahmood, PhD, has resigned his position as chief financial and business officer to serve as the chief executive officer of a private biotechnology company.

• Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights

  3/16/2023

  Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2022.

• Nkarta to Participate at Upcoming Investor Conferences

  2/9/2023

  Nkarta, Inc. today announced its participation at three upcoming investor conferences.

• Nkarta Promotes David R. Shook, M.D., to Chief Medical Officer

  1/9/2023

  Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced the promotion of David R. Shook, M.D., to the role of Chief Medical Officer.

• Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

  12/5/2022

  Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced positive updated data from its Phase 1 dose escalation study of NKX019 as monotherapy to treat patients with relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL).

• Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy ProgramCall scheduled for Monday, December 5, 2022 at 8:00 a.m. ET

  12/2/2022

  Nkarta, Inc. announced that it will host a conference call on Monday, December 5, 2022 at 8:00 a.m. ET to review updated clinical data from the ongoing clinical trial of NKX019, its CD19-directed CAR NK cell therapy candidate.

• Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights

  11/9/2022

  Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, reported financial results for the third quarter ended September 30, 2022.

• Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting

  11/7/2022

  Nkarta, Inc. (Nasdaq: NKTX) today announced the presentation of two preclinical data abstracts focused on its natural killer cell pipeline and proprietary manufacturing technology at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting and Pre-Conference Programs.

• Nkarta to Participate at Upcoming November 2022 Investor Conferences

  11/2/2022

  Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced its participation at three upcoming investor conferences.

• Nkarta Reports Second Quarter 2022 Financial Results and Corporate Highlights

  8/11/2022

  Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, reported financial results for the second quarter ended June 30, 2022.